Publications by authors named "JungHa Moon"
Background And Objectives: Cilostazol improves ischemic symptoms and prevents recurrence following cerebral infarction, and rosuvastatin reduces cholesterol levels. However, no reports exist on the pharmacokinetic interactions between these two drugs in healthy adults. This study evaluated the pharmacokinetic (PK) interactions and safety of cilostazol and rosuvastatin when co-administered to healthy male participants.
View Article and Find Full Text PDFThe combined cilostazol and rosuvastatin therapy is frequently used for coronary artery disease treatment. This open-label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed-dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions. Among 48 enrolled healthy adults, 38 completed the study.
View Article and Find Full Text PDFArticle Synopsis
- The study compared the pharmacokinetic (PK) and safety profiles of two fenofibric acid formulations, a 135 mg capsule and a 110 mg enteric-coated tablet, under fasting and fed conditions.
- Conducted as a crossover phase 1 clinical trial with 120 healthy Korean men, blood samples were analyzed to assess how each formulation performed over 72 hours.
- Results showed that the enteric-coated tablet had better bioavailability and was easier to swallow, taking longer to reach peak concentration than the capsule in both fasting and fed states.
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers.
Pharmaceuticals (Basel)
August 2022
Article Synopsis
- The study aimed to explore how atorvastatin (a statin) and omega-3 fatty acids interact at a pharmacokinetic level through a phase 1 trial.
- Researchers conducted the trial with 37 subjects who were administered different combinations of atorvastatin and omega-3 over specified periods to measure drug concentrations.
- Results showed significant pharmacokinetic interactions between atorvastatin and omega-3 fatty acids, as highlighted by the geometric mean ratios and 90% confidence intervals indicating deviations from typical bioequivalence standards.